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We examined the association of HTLV-1 Gag with tetraspanin-enriched microdomains in the plasma membrane. Immunofluorescent staining
and confocal image analysis showed that HTLV-1 Gag protein colocalized with CD82 and other tetraspanins at the plasma membrane of T cells.
HTLV-1 Gag, which is associated with the inner surface of the plasma membrane, was concentrated to the patches formed by antibody-mediated
cross-linking of CD82 on the cell surface. Also, CD82 and HTLV-1 Gag rapidly segregated to the immune synapse that is formed between Raji B
cells and Jurkat T cells in the presence of bacterial superantigen. CD82, which was immunoprecipitated from cell extracts prepared in Brij97
detergent conditions, was associated with the matrix (MA) protein. Stable interaction of MA and CD82 in Brij97-disrupted cell extracts required
Gag multimerization and proteolytic processing. The form of MA that coimmunoprecipitated with CD82 was a cysteine-linked homodimer. The
viral envelope glycoprotein was not required for the association of Gag with CD82-enriched membrane regions. In contrast to HTLV-1, HIV-1
Gag did not colocalize, cosegregate, or coimmunoprecipitate with CD82. Our data suggest that once at the plasma membrane, HTLV-1 virion
components associate with CD82-containing microdomains, which may facilitate the mobilization of nascent virions to sites of intercellular
adhesion.
Published by Elsevier Inc.Keywords: HTLV-1; Retrovirus; HIV-1; T cells; Immune synapse; Tetraspanins; CD82Introduction
Retrovirus Gag proteins are self-assembling units that are
sufficient for the formation and release of virus particles.
The matrix domain of Gag is responsible for targeting the
protein to the plasma membrane. Basic amino acids in MA
and N-terminal myristoylation are necessary for membrane
targeting of HTLV-1 Gag (Bouamr et al., 2003; Le Blanc et
al., 1999), and association of Gag with the plasma
membrane is essential for virion assembly (Rayne et al.,
2001). Because HTLV-1 infection is particularly dependent
on cell–cell contact, one might expect virus assembly and
release to be coordinated with the formation of the
intercellular adhesion interface. How virion components,
which are associated with the inner surface of the plasma0042-6822/$ - see front matter. Published by Elsevier Inc.
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E-mail address: derse@ncifcrf.gov (D. Derse).membrane, are mobilized to the site of cell–cell contact is
not known.
Both cellular proteins and the lipid composition of the
membrane influence the site where virus particles are
assembled and released. For example, HIV-1 Gag mainly
targets cholesterol-enriched lipid rafts to serve as platforms
for budding (Holm et al., 2003; Nguyen and Hildreth, 2000;
Pickl et al., 2001). Lipid rafts were initially identified by
their resistance to lysis in cold Triton X-100 and defined
later by their constituent lipids and proteins. Other mem-
brane domains and their components have been character-
ized using different detergents. One such domain is the
tetraspanin web, which is resistant to lysis by certain Brij
detergents (Claas et al., 2001; Stipp et al., 2001b). In
lymphocytes, tetraspanin webs serve as scaffolds that enable
assembly of specific proteins into complexes involved in
intra- and intercellular signaling, cell migration, adhesion,
and immunological synapse formation (Wright et al., 2004;
Yunta and Lazo, 2003; Levy and Shoham, 2005). The
tetraspanin membrane super family (TM4SF) consists of6) 194 – 204
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others that span the membrane four times; both N- and C-
termini are intracellular and are separated by two extracel-
lular and one intracellular loop. Each domain is responsible
for a specific function (Stipp et al., 2003). The second or
large extracellular loop (LEL) contains 4–8 cysteine resi-
dues that form 2–4 disulfide bonds that stabilize the loop
structure and is responsible for interactions with molecular
partners, such as integrins (Bienstock and Barrett, 2001).
Several properties of the tetraspanin web (reviewed in
Hemler, 2003) suggest that it could play an important role
in HTLV-1 infection. Tetraspanins have been shown to be
essential for cell adhesion and fusion (Hemler, 2003).
Tetraspanins engage laminin-binding integrins and are
rapidly mobilized towards the immunological synapse (IS)
formed between antigen presenting cells and cognate T cells
(Delaguillaumie et al., 2004). CD82 is the predominant
TMS4F protein on T cells and B cells, and it increases
several fold after cell activation (Shibagaki et al., 1998). In
particular, the engagement of CD82 on the surface of T cells
and antigen presenting cells results in increased LFA-1-
mediated cell–cell adhesion (Shibagaki et al., 1999) and
activation of Rho GTPases that lead to cytoskeleton
rearrangement and morphological changes (Delaguillaumie
et al., 2002). The molecular partners of CD82 are CD4,
CD8, HLA-DR, h1-integrin, EWI-2, EGFR and a number
other unidentified plasma membrane molecules (Kropshofer
et al., 2002; Odintsova et al., 2000; Zhang et al., 2003). In
addition to being part of the plasma membrane, tetraspanins
CD63, CD81 and CD82 are found in membranes of the late
endosomal compartments of lymphocytes and are enriched
in exosomes.
It has been reported that HTLV-1 Gag segregates to the
region of intercellular adhesion between infected and
uninfected lymphocytes, and that virus is transmitted across
this virological synapse (Igakura et al., 2003). Previous
work has not examined how Gag, which is associated with
the plasma membrane, gets mobilized to this adhesion
interface. We have begun to address this question by
defining the membrane microdomains with which HTLV-1
Gag associates and assembles into virus particles. We
employed confocal microscopy of HTLV-1-infected or
transfected T cells to show that Gag colocalizes with
tetraspanins in the plasma membrane. In particular, we
found that the matrix domain of HTLV-1 Gag interacts with
CD82-enriched plasma membrane microdomains by several
criteria. First, antibody-mediated cross-linking of CD82 on
the cell surface caused intracellular Gag to concentrate at the
patches of CD82. Second, immunological synapse (IS)
formation was used as a tool to show that Gag traffics
with CD82-enriched membrane microdomains that are
mobilized to this intercellular junction. Finally, CD82
coimmunoprecipitated with HTLV-1 MA from cell extracts
containing Brij 97 detergent but not in cell extracts prepared
in cold Triton X-100 buffers. In summary, HTLV-1 Gag, but
not HIV-1 Gag, is targeted to plasma membrane regions
with the hallmarks of tetraspanin microdomains.Results
Colocalization of HTLV-1 Gag and tetraspanins on the plasma
membrane of Jurkat T cells
Tetraspanins interact with each other and with various
plasma membrane molecules to organize multiprotein clusters
into distinct membrane microdomains. Tetraspanins can indi-
rectly connect these plasma membrane microdomains to the
cytoskeleton through interactions with integrins or by recruit-
ment of small adapter proteins. To examine the association of
HTLV-1 Gag with tetraspanin-enriched plasma membrane
microdomains, Jurkat cells were transfected with pCMV-
HT1, which expresses all HTLV-1 structural, enzymatic and
regulatory proteins, and fixed in formaldehyde 18 h later. The
tetraspanins CD53, CD81, CD82 or CD231 were stained on the
surface of fixed cells with appropriate primary monoclonal
antibodies and fluorescently labeled secondary antibodies.
Cells were then permeabilized and indirectly immunostained
for Gag using rabbit anti-p19(MA) antibodies. As shown in
Fig. 1, HTLV-1 Gag was detected at the plasma membrane of
Jurkat cells in the form of distinct spots, which are likely to be
areas of virion assembly. These localized sites of Gag
aggregation were coincident with the areas where the tetra-
spanins CD82, CD81, CD53 and CD231 (also known as A15
or TALLA) accumulated at the cell surface.
We also investigated the colocalization of Gag with cellular
proteins that were reported to be either constituents of the
tetraspanin web or to be excluded from these microdomains.
h1-Integrins and MHC-I were previously shown to be
molecular partners of tetraspanins (Berditchevski, 2001;
Lagaudriere-Gesbert et al., 1997). Although the colocalization
of Gag and h1-integrin at the surface of Jurkat cells is obvious,
colocalization of MHC-I and Gag is not (Fig. 1). The latter
result may simply reflect a lower stoichiometry of interaction
between MHC-I and tetraspanins compared to h1-integrin.
CD3 is not considered to be a molecular partner of CD81 or
CD82 but has been shown to enter the tetraspanin web upon
IS formation (Mittelbrunn et al., 2002). In transfected Jurkat
cells, only a fraction of the total cell surface CD3 protein
colocalized with Gag (Fig. 1). Furthermore, after anti-CD3
antibody cross-linking, the patches of CD3 did not correspond
to the sites of aggregated Gag (data not shown). CD98 is a
heterodimeric, transmembrane protein, which is often used as
a negative control in TM4SF studies (Zhang et al., 2001).
CD98 did not colocalize with HTLV-1 Gag (Fig. 1). Thus,
tetraspanins and proteins known to associate with tetraspanins
colocalized with the spots of HTLV-1 Gag at the plasma
membrane of T cells.
Because CD82 plays essential roles in T-lymphocyte
function, we examined its interactions with HTLV-1 Gag in
greater detail. We first compared the distribution of CD82 on
the surface of Jurkat cells in the absence or presence of HTLV-
1 Gag expression. In cells that do not express HTLV-1 Gag,
CD82 stained brightly and was distributed uniformly on the
plasma membrane (Fig. 2A, far right panel). In cells that
express HTLV-1, CD82 and Gag colocalized in discrete
Fig. 2. Plasma membrane colocalization of CD82 with HTLV-1 Gag. (A
Staining of CD82 on the cell surface was performed as in Fig. 1. The panel a
the far right hand side shows the cell surface distribution of CD82 on mock
transfected Jurkat cells. (B) Intracellular staining of CD82 and HTLV-1 Gag
Both CD82 and HTLV-1 Gag were stained after cells were fixed and
permeabilized. (C) CD82 was cross-linked and stained on live cells with
anti-CD82 monoclonal antibody, followed by anti-mouse secondary antibody
in suspension. Cells were then transferred to poly-lysine-coated slides, fixed
permeabilized and stained for intracellular Gag. In panels A–C Jurkat cells
were transfected with pCMV-HT1. CD82 was stained with B-L2 monoclona
antibody and Alexa-546 conjugated secondary antibody. HTLV-1 Gag was
stained with rabbit anti-p19 antibody plus Alexa-488 conjugated donkey anti
rabbit antibody. (D) Jurkat cells were transfected with pCMVD8.2R. CD82 was
cross-linked and then HIV-1 Gag protein was stained with anti-p24 (CA
monoclonal antibody clone 39/5.4A (Zeptometrix), which was prelabeled with
Alexa-488. (E) Jurkat cells were transfected with pCMV-HIV1Gag-CFP, which
expresses a HIV-1 Gag-eCFP fusion protein. Cell surface CD82 was cross
linked as described above (C). Representative images of cells with intermediate
levels of viral protein expression are shown (0.9-Am optical slice through the
center plane of cells).
Fig. 1. Colocalization of HTLV-1 Gag with lymphocyte tetraspanins and their
molecular partners. Jurkat cells were transfected with the HTLV-1 expression
plasmid pCMV-HT1. 16 h later, cells were transferred to poly-lysine-coated
slides and fixed; cell surface antigens were then stained with primary
monoclonal antibodies against the indicated proteins followed by Alexa-546
conjugated secondary antibodies. Cells were then permeabilized, and intracel-
lular HTLV-1 Gag was detected with rabbit anti-p19 (MA) antibody and Alexa-
488 conjugated secondary antibody. The data represent 0.9-Am optical planes
through the center of the cells.
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brane (Fig. 2A). We next examined whether intracellular CD82
was associated with HTLV-1 Gag by staining for CD82 and
MA simultaneously after cell permeabilization (Fig. 2B).
HTLV-1 Gag was detected predominantly at the plasma
membrane and was not detected with intracellular CD82,
suggesting that Gag is not trafficking with CD82 from
intracellular vesicles to the plasma membrane.To examine the association of HTLV-1 Gag with CD82-
enriched plasma membrane microdomains further, we analyzed
the localization of Gag after cross-linking cell surface CD82
with anti-CD82 antibody. The cross-linking of CD82 on the
cell surface caused the spots of Gag and CD82 to coalesce into
large patches where both proteins remained together (Fig. 2C).
Similar results were obtained with chronically HTLV-1-
infected T cells and HTLV-1-transfected B cell lines (data not
shown). HIV-1 Gag, in contrast to HTLV-1 Gag, did not
colocalize with capped CD82 (Figs. 2D and E). In cells
transfected with pCMV-D8.2R, which expresses all HIV-1
proteins except Env, immunofluorescent staining with anti-p24
(CA) antibody detected Gag mainly in the cytoplasm. Similar
experiments in which Jurkat cells were transfected with pCMV-
HIV1Gag-CFP, a plasmid that expresses only a HIV-1 Gag-)
t
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colocalize with cross-linked CD82 (Fig. 2E). Together, these
experiments indicate that HTLV-1 Gag, but not HIV-1 Gag, is
targeted to CD82-enriched microdomains in the plasma
membrane.
To determine whether the colocalization of HTLV-1 Gag with
CD82-containing membrane domains was dependent on the
integrity of the cytoskeleton, we examined the effects of agents
that disrupt either actin or tubulin polymerization (Fig. 3). Jurkat
cells were transfected with pCMV-HT1, treated overnight with
cytochalasin E, then cross-linked with anti-CD82 antiserum and
stained for Gag andCD82. Cells were also stainedwith falloidin-
red to determine the extent of inhibition of actin polymerization
by cytochalasin E. Although cytochalasin E treatment disrupted
actin networks, it did not affect colocalization of HTLV-1 Gag
with cross-linked CD82 (Figs. 3A and B). Likewise, inhibition
of tubulin polymerization by nocodazole, had no affect on Gag
and CD82 colocalization (Figs. 3C and D). These data indicate
that HTLV-1 Gag directly interacts with plasma membrane
microdomains that contain CD82. HTLV-1 Gag on the inner
surface of the plasma membrane is pulled into the patches of
CD82 created by cross-linking CD82 on the outer surface of the
membrane.Fig. 3. Colocalization of CD82 with HTLV-1 Gag protein is not dependent on
cell cytoskeleton rearrangement. Jurkat cells were transfected with pCMV-HT1
and incubated without inhibitors (A and C), with 5 AM cytochalasin E (B), or
with 33 nM nocodazole (D) overnight. Cells were stained with anti-human
CD82 monoclonal antibody (Serotec), cross-linked with Alexa-350 conjugated
goat anti-mouse antibody and transferred to poly-lysine slides. After fixation
and permeabilization, cells were stained with rabbit anti-p19 antibody followed
by Alexa-488 conjugated donkey anti-rabbit antibody. (A and B) F-actin was
stained with Alexa Fluor 546 phalloidin (Molecular Probes). Acquired images
were pseudo-colored as follows CD82, red; HTLV-1 Gag, green; and actin,
blue. (C and D) CD82 was cross-linked and stained as above. Cells were
transferred to slides, fixed and permeabilized with cold 100% methanol for 5
min. HTLV-1 Gag was stained as described in Fig. 1. Tubulin filaments were
stained with a mixture of anti-a and anti-h-tubulin antibodies, which were
prelabeled with Alexa-350. Panels show confocal images through the middle
plane of cells.Trafficking of HTLV-1 Gag with CD82 to the immunological
synapse
An IS can be induced to form between Raji B cells and
Jurkat T cells with bacterial superantigen SEE, which bridges
the TCR on T cells and MHC-II on antigen presenting cells
(APCs) (Criado and Madrenas, 2004; Morgan et al., 2001;
Sancho et al., 2002). We have used this system to examine
whether Gag traffics with CD82-enriched plasma membrane
microdomains that are mobilized to the IS by transfecting
Jurkat cells prior to SEE treatment. In cells that were
transfected with pCMV-CD82-eCFP, the CFP-tagged CD82
fusion protein accumulated at the IS (Fig. 4A, top), as
previously shown for an analogous CD82 fusion protein
(Delaguillaumie et al., 2002). The wild-type CD82 protein,
detected by indirect immunofluorescent staining, was likewise
mobilized to the IS (Fig. 4A, lower); however, visualizing
CD82 in this manner was less desirable because endogenous
CD82 in both Jurkat and Raji cells was detected. Trafficking of
HTLV-1 Gag to the IS was analyzed by transfecting Jurkat cells
with pCMV-HTDXho (the Env-minus HTLV-1 vector) and
staining with anti-p19 antibody (Fig. 4A, lower) or transfecting
cells with pCMV-DX-MAYFP, which encodes Gag with eYFP
embedded in the MA domain of Gag (Fig. 4A upper). Both
wild-type and fluorescent protein tagged forms of HTLV-1 Gag
segregated to the IS (Fig. 4A). Jurkat cells transfected with
pCMV-HIV-MAYFP, which expresses HIV-1 Gag with eYFP
embedded in MA did not accumulate fluorescent fusion protein
at the IS, suggesting that the Gag proteins from HTLV-1 and
HIV-1 interact with different membrane microdomains (Fig.
4B). Similar results were obtained when we used plasmids
expressing wild type HIV-1 Gag or when Raji cells were
transfected with virus expression plasmids (data not shown). In
summary, HTLV-1 Gag associates with CD82-enriched plasma
membrane regions that are concentrated at an IS formed
between Jurkat and Raji cells.
HTLV-1 MA and CD82 can be coprecipitated after Brij97 lysis
The tetraspanin web can be distinguished from other
membrane domains, such as the classic lipid raft, based on
detergent lysis conditions, which are dependent on the lipid
composition. For example, tetraspanin microdomains are
disrupted in cold Triton X-100 buffers in which lipid rafts
are preserved, whereas lysis buffers containing Brij detergents
preserve tetraspanin membrane domains and have been used to
study protein interactions within the tetraspanin web (Charrin
et al., 2001; Stipp et al., 2001a). We examined the association
of HTLV-1 proteins with the tetraspanin web by immunopre-
cipitation and immunoblotting. Chronically infected MS9 cells
were extracted in buffer containing Brij97 detergent, and
proteins were precipitated using a negative control IgG, anti-
p19 (MA) or anti-CD82 antibodies. The immunoprecipitates
were run on duplicate immunoblots and probed with HRP-
conjugated anti-p19 (MA) or anti-CD82 antibodies (Fig. 5A).
Neither CD82 nor HTLV-1 MA was detected in immunopre-
cipitates with IgG control serum. A small fraction of the total
Fig. 5. Role of detergent treatment and cholesterol in association of HTLV-1
Gag and CD82. (A) Reciprocal coimmunoprecipitation between CD82 and
HTLV-1 MA. Chronically infected MS9 cells were lysed in buffer containing
1% Brij 97 detergent supplemented with Ca++ and Mg++. Cell extracts were
precleared with normal mouse IgG and then precipitated with IgG1 isotype
control (BD Pharmingen), anti-HTLV-1 p19 (46/6.11.1.3) or anti-CD82 (B-L2
antibodies. After washing, samples were resolved on 4–12% SDS-PAGE unde
nonreducing (upper panel) or reducing (lower panel) conditions. The blots were
probed with anti-p19 (46/6.11.1.3) or anti-CD82 (MC8D12) antibodies
conjugated with HRP. (B) Coimmunoprecipitation of CD82 and HTLV-1 MA
depends on the detergent lysis buffer conditions. MS9 cells and concentrated
virions were extracted using the indicated detergents. Anti-CD82 B-L2
immunoprecipitates were run on SDS-PAGE under nonreducing conditions
blotted and stained with biotinylated anti-MA antibody, followed by HRP
conjugated anti-biotin secondary antibody. (C and D) Cholesterol depletion has
no effect on the colocalization of CD82 and HTLV-1 Gag. pCMV-HT1
transfected Jurkat cells were stained for CD82 and Gag as described in Fig. 2C
Before antibody-mediated cross-linking of CD82, cells were treated with PBS
alone (C) or with 10 mM MhCD in PBS (D) for 20 min and washed with PBS
twice. Membrane-bound cholesterol was visualized by staining with Filipin III
Finally, cells were permeabilized with 0.1% saponin and stained fo
intracellular Gag.
Fig. 4. Mobilization of HTLV-1 Gag and CD82 tetraspanin towards the IS. (A)
Jurkat cells were cotransfected with pCMVHTDX-MAYFP and pCMV-CD82-
eCFP (upper panel) or with pCMVHTDXho and pCMV-CD82 (lower panel).
(B) Jurkat cells were cotransfected with pCMV-HIV-MAYFP and pCMV-
CD82-eCFP. 16 h after transfection, Jurkat cells were mixed with Raji cells at a
ratio of 2:1 in the presence of 2 Ag/ml SEE in serum-free medium, incubated at
37 -C for 40 min and transferred to poly-l-lysine-coated glass coverslips for
another 20 min. After fixation, cell surface HLA-DR antigen (expressed only
on Raji cells) was stained with TU36 monoclonal antibody and Alexa-546
conjugated secondary antibody. For the lower panel in part (A), cells were
permeabilized and stained with anti-CD82 and anti-p19 antibodies as in Fig. 2B.
Approximately 50% of cells treated with SEE formed tight T cell –B cell
contacts that withstood mechanical shearing sufficient to break up nonspecific
aggregates. Without SEE treatment, conjugates were not observed and patches
of Gag and CD82 were randomly distributed on the Jurkat cell surface. 60% to
80% of conjugated Jurkat cells with an intermediate level of Gag and CD82
expression showed segregation of HTLV-1 Gag and CD82 towards the synapse.
Images are representative of several experiments and show 0.9-Am optical slices
through the center plane of cell conjugates for each fluorescent channel.
D. Mazurov et al. / Virology 346 (2006) 194–204198CD82 was detected in the anti-p19 (MA) immunoprecipitate
and a larger fraction of the total MA was detected in the anti-
CD82 precipitate (Fig. 5A).
We next examined the immunoprecipitation of HTLV-1
MA and CD82 from cells and virions extracted in various
detergent lysis conditions. HTLV-1 MA coprecipitated with
CD82 when cells were extracted in buffers containing Brij97
(Fig. 5B); addition of Ca++ and Mg++ or EDTA to the
Brij97 lysis buffer had little effect on the amount of MA
recovered. Extraction of cells with buffers containing Triton
X-100 or CHAPS detergents resulted in the disruption of the
membrane complexes containing MA and CD82. We also
examined whether MA and CD82 could be coprecipitated
from virus particles concentrated from MS9 cell culture
supernatants and found that complexes were resistant to
disruption by a larger spectrum of detergents. HTLV-1 MA
coprecipitated with CD82 from virions extracted in buffers
containing CHAPS, Brij97 and Triton X-100. The amount of
MA associated with CD82 was greatest in Brij97 plus Ca++
and Mg++ conditions but could be detected in Triton X-100
(Fig. 5B).Due to the fact that the anti-CD82 monoclonal antibody
only recognizes the nonreduced form of CD82, SDS gels for
immunoblotting were run under nonreducing conditions. Under
these conditions, about half of the total MA protein in cell
extracts and the majority of MA in viral extracts migrate as a)
r
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Fig. 6. Viral determinants of colocalization of HTLV-1 Gag with CD82. Jurkat
cells were transfected with the following HTLV-1 expression plasmids: pCMV-
HT1 (wt), pCMVHTDXTax9Q (Env and Tax deficient), pCMVHT-PR (PR
deficient) or pCMV-MA-RRE (expresses only MA). After cross-linking of
CD82 on the surface of live cells, Jurkat cells were fixed, permeabilized by
saponin and stained with rabbit anti-p19 (MA) and Alexa-488 conjugated anti-
rabbit secondary antibody. HTLV-1 Gag was stained in cells transfected with
pCMVHT-PR with anti-p19 antibodies after first denaturing and fixing cells in
cold 100% methanol. Confocal images of representative cells are shown.
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GH and DD, unpublished observation). Although only a
fraction of MA exists as a dimer in cell extracts (Fig. 7), the
MA dimer is the predominant form of the protein that
coprecipitates with CD82 (Fig. 5B). In summary, membrane
complexes containing CD82 and the MA dimer are stable in
detergent lysis conditions that preserve tetraspanin web
domains.
To further define the membrane microdomain where CD82
and HTLV-1 Gag interact, we investigated the role of
cholesterol in its maintenance. Cholesterol plays a crucial role
in the preservation of lipid rafts (Kabouridis et al., 2000) but
only a minor role in tetraspanin complexes (Claas et al., 2001).
Cholesterol is thought to contribute to lateral interactions
among tetraspanin molecules on the plasma membrane
(Charrin et al., 2003), as well as between lipid rafts and
tetraspanin enriched domains (Delaguillaumie et al., 2004). We
tested whether depletion of cholesterol affects Gag and CD82
colocalization. Jurkat cells transfected with pCMV-HT1 were
treated with 10 mM methyl-h-cyclodextrin (MhCD) for 20 min
followed immediately by CD82 cross-linking and immunoflu-
orescent staining. CD82 did not cap as efficiently on the
surface of cholesterol-depleted cells (Fig. 5D) as on untreated
cells (Fig. 5C), suggesting that cholesterol is important for
inter-tetraspanin interactions in the membrane. However, Gag
remained colocalized with patches of cross-linked CD82 after
cholesterol depletion (Fig. 5D), indicating that cholesterol is
dispensable for the association of Gag with CD82-containing
membrane domains.
Proteolytic cleavage and multimerization of Gag are both
necessary for its close association with CD82 in cells and
virions
To determine whether other proteins encoded by HTLV-1
have an impact on the colocalization of CD82 with Gag, we
transfected Jurkat cells with pCMVHTDXTax9Q, a plasmid
that expresses all HTLV-1 proteins except for Env and Tax.
Confocal microscopy revealed that Gag and CD82 colocalized
in the same way in cells transfected with pCMV-HT1 or
pCMVHTDXTax9Q, indicating that colocalization did not
require Env and Tax expression (Fig. 6). In addition, MA
coimmunoprecipitated with CD82 in cell and VLP extracts
from cells cotransfected with pCMV-CD82 and either pCMV-
HT1 or pCMVHTDXTax9Q (Fig. 7).
We next asked whether the MA domain of Gag expressed
by itself can associate with CD82-containing membrane
domains. Jurkat cells were transfected with pCMV-MA-
RRE, a plasmid that expresses the N-terminal, 132 amino
acid, HTLV-1 MA protein. The MA protein expressed in this
way was targeted to the plasma membrane but did not
colocalize with cross-linked CD82 (Fig. 6). Immunostaining
showed a uniform distribution of MA on the cell surface rather
than the punctate distribution seen with full-length Gag,
probably because MA by itself cannot multimerize or
assemble into particles. Also, MA and CD82 did not
coimmunoprecipitate in extracts from 293 T cells cotransfectedwith pCMV-CD82 and pCMV-MA-RRE expression plasmids
(Fig. 7).
Finally, we examined the ability of the Gag precursor to
interact with CD82 using an HTLV-1 expression construct with
a defect in the catalytic site of protease, pCMVHT-PR. In
transfected Jurkat cells, the Gag precursor colocalized with
cross-linked CD82 on the cell surface (Fig. 6). However, the
Gag precursor protein did not immunoprecipitate with CD82
from extracts of 293 T cells that had been cotransfected with
pCMV-CD82 and pCMVHT-PR expression plasmids (Fig. 7).
The same lack of interaction was also observed in VLP
extracts. This result indicates that the affinity of MA for the
CD82-containing compartment of the membrane is increased
following Gag maturation. It is important to note that CD82
was abundant in concentrated supernatants from cells that
released VLPs (pCMV-HT1 and pCMVHT-PR) in contrast to
cells that did not (no HTLV-1 or pCMV-MA-RRE) (Fig 7,
middle panel). These data suggest that VLPs are budding from
CD82-enriched membrane regions. In all, these experiments
indicate that HTLV-1 Gag is targeted to CD82-enriched plasma
membrane domains, and that subsequent maturation of Gag
may induce conformational changes in MA that enhance its
interaction with CD82-containing membranes.
Discussion
In this report, we have shown that HTLV-1 Gag associates
with TMS4F-enriched plasma membrane microdomains in
Jurkat T cells. We focused our attention on the TMS4F protein
Fig. 7. Viral determinants of HTLV-1 Gag-CD82 interaction and of CD82 recruitment into VLPs. 293 T cells were transiently transfected with pCMV-CD82 in
combination with either pCMV-HT1 (wt), pCMVHTDXho (Env deficient), pCMVHT-PR (PR deficient) or pCMV-MA-RRE (expresses only MA), as indicated at
the top of the figure. Brij 97 (Ca++, Mg++) extracts of cells (on the left hand side) and virus-like particles (VLP, on the right hand side) were analyzed by
immunoblotting. Immunoblots of cell and VLP extracts were probed with anti-p19 antibody (upper panels) and with anti-CD82 antibody (middle panels). The lower
panels show anti-CD82 immunoprecipitates probed with anti-p19 antibody.
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is important for T cell functions, particularly those associated
with cellular adhesion. Association of HTLV-1 Gag with
CD82-enriched membrane domains is supported by several
lines of experimental evidence. First, expression of HTLV-1
Gag changed the appearance of CD82 on the cell surface from
a uniformly dispersed pattern to discrete spots where CD82 and
Gag colocalized. We believe that this change is due to Gag
multimerization, which causes CD82-containing membrane
microdomains to coalesce into larger patches in a manner
analogous to capping, but from the inside. Second, antibody-
mediated cross-linking of CD82 on the cell surface caused
Gag, which is associated with the inner surface of the plasma
membrane, to concentrate with the large patches of CD82.
Third, HTLV-1 Gag along with CD82 concentrated at the site
of intercellular adhesion when an IS was formed between
HTLV-1-transfected Jurkat cells and Raji B cells. Finally,
HTLV-1 MA could be immunoprecipitated with CD82 when
cells were extracted in detergents that preserve tetraspanin
microdomains. The HTLV-1 Gag-CD82 interaction resembles
the association between activated protein kinase C (PKC) and
CD82 (Zhang et al., 2001); Gag and activated PKC are both
cytoplasmic proteins that interact with the cytoplasmic face of
CD82-enriched plasma membrane regions.
The association of HTLV-1 Gag with CD82-enriched
plasma membrane microdomains is specific. HIV-1 Gag did
not colocalize or coimmunoprecipitate with CD82, indicating
that HTLV-1 Gag and HIV-1 Gag target different plasmamembrane microdomains in Jurkat T cells. Although N-
terminal myristoylation and basic amino acid residues in the
MA domain of Gag proteins are necessary for membrane
association, additional motifs in Gag are required to direct Gag
to specific membrane microdomains. The association of HTLV-
1 Gag with CD82-enriched membrane regions did not require
Tax or Env in the experiments shown here, but we cannot rule
out the possibility that Env affects virion assembly in the
context of cell-to-cell transmission. It was previously reported
that HTLV-1 Env interacts with CD82 (Pique et al., 2000), and
it is possible that this interaction facilitates incorporation of
Env into virus particles. We also showed here that the
cytoskeleton is not involved in the association of Gag and
CD82-enriched membrane microdomains in CD82 cross-
linking experiments. However, this result should not be
confused with the role of the cytoskeleton in directing the
movement and distribution of TMS4F-enriched domains on the
cell surface.
The HTLV-1 Gag precursor protein targets the plasma
membrane and colocalizes with CD82 in cells, but it did not
coprecipitate with CD82 from cell extracts. Likewise, expres-
sion of the MA protein by itself resulted in a protein that was
targeted to the plasma membrane but could not form multimers
and did not coimmunoprecipitate with CD82 in Brij97
detergent lysis conditions. These results suggest that multi-
merization and proteolytic processing of the Gag precursor are
likely to induce structural changes in the MA domain that alter
its interactions with CD82-enriched membrane regions. Anal-
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which alter its membrane affinity (Perez-Caballero et al., 2004;
Tang et al., 2004). We also observed that MA can exist as a
cysteine-linked homodimer (Mazurov, Heidecker and Derse,
unpublished observation) as recently reported by Rayne et al.
(2004); CD82 immunoprecipitated predominantly with the
dimeric form of MA. Hence, the MA domain that interacts with
CD82 with highest affinity in Brij97 conditions is only
revealed following Gag multimerization, proteolytic processing
and MA dimerization.
Even though cell-free HTLV-1 particles can infect cells in
vitro (Derse et al., 2001; Fan et al., 1992), considerable
evidence supports the notion that HTLV-1 is transmitted by
cell–cell contact in vivo (Bangham, 2003; Derse and
Heidecker, 2003). HTLV-1 virion components were previous-
ly shown to concentrate at, and transfer across, a virological
synapse formed between an infected and an uninfected
lymphocyte (Igakura et al., 2003). We suggest that in this
mode of virus transmission, virus assembly and release will
be coordinated with the architectural changes leading to
formation of the virological synapse. HTLV-1 assembly is
dependent on the association of Gag with the plasma
membrane (Le Blanc et al., 1999; Rayne et al., 2001). We
hypothesized that by interacting with CD82-enriched plasma
membrane microdomains, which are involved in intercellular
adhesion (Delaguillaumie et al., 2002), virion assembly would
be directed to the synapse. While we showed that HTLV-1
Gag and CD82 segregate to an IS, we have not yet shown
that this occurs in a VS. The IS and VS share many of the
same components and mechanisms for structural remodeling
of the cytoskeleton (Piguet and Sattentau, 2004). However,
many details of the VS have yet to be explored. We are
currently examining the roles of CD82 and other TMS4F
proteins in HTLV-1 Env-induced VS formation and in cell–
cell infection.
Materials and methods
Cell culture
CD4+ Jurkat E6-1 cells and Raji B cells were maintained in
RPMI 1640 medium containing 10% fetal calf serum, 2 mM
glutamine, 100 U of penicillin per ml and 0.1 mg of
streptomycin per ml. HTLV-1-infected cell line MS9 was
maintained in the same medium containing 10 ng/ml of IL-2.
293FT human kidney cells were grown in Dulbecco’s
modified Eagle’s medium containing 10% fetal calf serum, 2
mM glutamine, 100 U of penicillin per ml, 0.1 mg of
streptomycin per ml, nonessential amino acids and 1 mM
sodium pyruvate (all tissue culture reagents were from
Invitrogen Life Technologies).
Antibodies and reagents
Anti-human tetraspanin antibodies were anti-CD82 clone
B-L2 (Serotec, UK), anti-CD82 clone MC8D12 (gift from
Filatov A.V., Institute of Immunology, Moscow, Russia), anti-CD81 clone 1D6 (Serotec, UK), anti-CD53 and anti-CD231
clone H1-A12 (BD Pharmingen). Other antibodies against
human leukocyte antigens were anti-integrin h1 (P5D2)
(Santa Cruz Biotechnology), anti-MHC-I clone W6/32 (Sig-
ma), anti-HLA-DR clone TU36, anti-CD3 clone UCHT1 and
anti-CD98 clone UM7F8 (BD Pharmingen). Monoclonal anti-
a-tubulin clone B-5-1-2 and anti-h-tubulin clone TUB 2.1
Abs were purchased from Sigma. Antiviral Abs were HTLV-1
p19 Mabs clone 46/6.11.1.3, anti-HIV p24 Mabs clone 39/
5.4A and anti-HIV p17 Mabs clone 32/5.8.42 (all from
Zeptometrix Corp.). Rabbit polyclonal anti-HTLV-1 p19 was
a gift from Stephen Oroszlan, NCI-Frederick. Biotinylated
p19 Mabs were prepared using Mini-biotin-XX Protein
Labeling Kit (Molecular Probes) according to the manufac-
turer’s protocol. Secondary Abs were donkey anti-rabbit
Alexa Fluor 488, goat anti-mouse Alexa Fluor 350, 488,
546 (all from Molecular Probes), horseradish peroxidase
(HRP)-conjugated anti-biotin and anti-mouse antibodies (Cell
Signaling Technology). Nocodazole, Cytochalasin E, C.
difficiles Toxin B and cholesterol chelator methyl-h-cyclo-
dextrin, as well as cholesterol staining reagent Filipin III were
from Sigma. Staphylococcal enterotoxin E was from Toxin
Technology, Inc. (Sarasota, Florida).
Plasmids and transfections
The expression plasmid pCMV-CD82, encoding human
CD82, was generated from poly A+ RNA by RT-PCR using
standard protocols. Fluorescent protein-tagged CD82 was made
by fusing the eCFP gene to the 5V end of the CD82 gene; a
linker encoding the amino acids GAGAS was present between
eCFP and CD82 proteins. The eCFP-tagged CD82 fusion
protein behaved like wild-type CD82 in transfected cells, as
reported previously (Delaguillaumie et al., 2002). The HTLV-1
expression plasmid pCMV-HT1 expresses gag, pro, pol, env,
tax and rex genes under the control of the cytomegalovirus
immediate early (CMV) promoter (Derse et al., 1996).
pCMVHTDXho was derived from pCMV-HT1 and is defective
for Env expression. pCMVHTDXTax9Q has a stop codon
inserted at codon 9 of tax and is deficient for both Tax and Env
expression. pCMVHT-PR has a 2-amino acid change (DT to
AS) in the catalytic site of the protease gene; although all virus
proteins are made and VLPs are released from cells, there is no
proteolytic maturation of precursor polyproteins (Heidecker et
al., 2004). pCMVRRE-MA expresses the HTLV-1 matrix
protein and two amino acids of capsid. pCMVHTDX-MAYFP
was derived from pCMVHTDXho by inserting the eYFP gene
into the 3V end of the MA domain of Gag. The in-frame
insertion places the eYFP coding sequence between codons for
amino acids 127 and 128 of Gag (..TAP^QVL..). The linker
between MA and the N-terminus of eYFP is the amino acid
sequence SGGG; the linker at the C-terminus of eYFP contains
the 2 amino acid sequence GG. Cells transfected with
pCMVHTDX-MAYFP release VLPs in which Gag is pro-
cessed normally (data not shown). The HIV-1 expression
vector pCMVD8.2R expresses all HIV-1 proteins except Env
(Naldini et al., 1996). pCMV-HIV1Gag-CFP encodes a HIV-1
D. Mazurov et al. / Virology 346 (2006) 194–204202Gag-eCFP fusion protein where the eCFP gene was joined to
the 3V end of the gag gene in pCMVD8.2R; this vector does not
express protease. pCMV-HIV-MAYFP was derived from
pCMVD8.2R by imbedding the eYFP gene in the 3V end of
the MA domain of Gag and is analogous to the vector
reported recently by Muller et al. (2004). The insertion places
the eYFP open reading frame between codons for amino acids
128 and 129 of HIV-1 Gag (..NQA^SQN..). The linkers bet-
ween Gag and eYFP are the same as in the HTLV-1 plasmid
pCMVHTDX-MAYFP described above.
293 T cells were transiently transfected by calcium
phosphate-DNA coprecipitation as previously described. Jurkat
and Raji cells (5  106 cells per transfection) were electro-
porated with 5 Ag of plasmid DNA using Nucleofector Kit V,
program S-18, and NucleofectorTM I apparatus (Amaxa
Biosystems) according to the manufacturer’s instructions.
Antibody-induced surface cross-linking and fluorescent
microscopy
Sixteen hours after transfection, live Jurkat cells were
isolated by gradient centrifugation using lymphocyte separa-
tion medium (ICN), washed with phosphate-buffered saline
(PBS), incubated in PBS with primary antibody at a final
concentration 1 Ag/ml for 20 min at room temperature and
washed with PBS 2 times. The cross-linking of surface
molecules was done with goat anti-mouse Alexa-conjugated
Abs (Molecular Probes) in complete medium for 30 min at
37 -C, followed by PBS washing. Cells were adhered to
poly-l-lysine (Sigma) coated coverslips in PBS for 30 min,
fixed with 4% paraformaldehyde (Sigma) in PBS for 30
min, washed and permeabilized for 30 min with 0.1%
saponin (Sigma), containing 1% normal goat serum in PBS.
HTLV-1 matrix protein was stained with polyclonal rabbit
anti-p19 Abs that were added directly to permeabilization
solution for 30 min, washed with permeabilization solution
once and with PBS two times. Secondary donkey anti-
mouse Alexa 488 Abs was added in permeabilizing solution
in the presence of 1% of normal donkey serum. In some
experiments, HTLV-1 Gag was stained with mouse anti-p19
(MA) clone 46/6.11.1.3 that was labeled with Alexa-
conjugated secondary Abs by using Zenon Kit (Molecular
Probes). After washing, coverslips were transferred to slides
and maintained in ProLong Antifade Reagent (Molecular
Probes). Slides were analyzed on a Zeiss LSM 510 Inverted
Laser Scan Microscope. Staining of cells with labeled
secondary antibodies without prior incubation with primary
antibodies was negative.
Immunoprecipitation and Western blot analysis
Virus particles were concentrated from supernatants of
MS9 cells and transfected 293 T cells. Supernatants were
collected and filtered through 0.45-Am filter, overlaid on a
20% glycerol-PBS cushion and centrifuged at 30,000 rpm for
90 min. Cells were washed with PBS twice. Viral and cell
pellets of each culture (2  107 MS9 or one 10-cm dish of293 cells) were each lysed in 1 ml of ice-cold buffer,
containing 1% Brij97 (Sigma), 1mM Ca++, 1 mM Mg++, 150
mM NaCl, 10 mM Tris pH 7.5 and protein inhibitor cocktail
(Complete Mini EDTA free, Roche Diagn. Corp.). In some
experiments, pellets were lysed with 1% Triton X-100
(Sigma) or 1% CHAPS (Sigma) without Ca++ and Mg++
and with addition of 1 mM EDTA. After 1-h extraction at 4
-C, insoluble material was removed by centrifugation at
20,000  g for 10 min, and lysates were cleared at 4 -C once
with a mixture of normal mouse and rabbit IgG-loaded
protein A/G PLUS Agarose (Santa Cruz Biotechnology) for 1
h and once with protein A/G PLUS Agarose. Immunopre-
cipitation was done with protein A/G PLUS Agarose beads,
preloaded by specific monoclonal Abs overnight at 4 -C.
After washing four times with ice-cold lysis buffer, immune
complexes were eluted by heating at 80 -C in SDS sample
buffer with or without Sample Reducing Agent, resolved by
4–12% SDS-PAGE and transferred to Immobilon membranes
(GE Health). Blots were blocked with 5% nonfat milk in PBS
with 0.02% Tween (Sigma) (PBST), probed with primary Abs
in the case of direct immunoblots or with biotinylated Mabs
when probing blots of immunoprecipitates, washed with
PBST, developed with HRP-conjugated secondary Abs or
HRP-conjugated anti-biotin Abs (Cell Signaling Technology)
washed again and detected with LumiGLO Reagent A and B
(Cell Signaling Technology). In some experiments, Zenon
HRP labeling Kit (Molecular Probes) was used to directly
label Mabs.
Cell–cell junction formation assay
Jurkat cells were transfected and enriched for live cells as
described above. Jurkat and Raji cells were mixed at a 2:1 ratio
in 200 Al of OptiMEM medium, 0.4 Ag of SEE was added, and
cells were incubated for 40 min at 37 -C. After gentle
resuspension to break up large cellular clumps, 100 Al of the
mixture was transferred to poly-l-lysine-coated coverslips and
allowed to attach for 20 min. Cells were fixed and stained as
described above.Acknowledgments
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